Vanguard Global Advisers
RLMD icon

Vanguard Global Advisers’s Relmada Therapeutics RLMD Stock Holding History

Vanguard Global Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
44,163
+15,038
+52% +$105K ﹤0.01% 2324
2026
Q1 		$203K Buy
+29,125
New +$138K ﹤0.01% 2437

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's RLMD Position: Q2 2026 in Review

Vanguard Global Advisers increased its Relmada Therapeutics (RLMD) stake by 52% in Q2 2026, buying an estimated $105K and bringing the position to 44,163 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Vanguard Global Advisers first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Vanguard Global Advisers held 44,163 shares of Relmada Therapeutics worth $306K as of Q2 2026.
  • Vanguard Global Advisers bought 15,038 Relmada Therapeutics shares in Q2 2026, an estimated $105K.
  • Relmada Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2324 holding.
  • Vanguard Global Advisers first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.